Keisho Chin

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 161 publications

Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer.

Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer.

Journal: ESMO gastrointestinal oncology

Published: August 12, 2026

The geriatric 8 score as a predictor of postoperative outcomes in elderly patients undergoing esophagectomy.

The geriatric 8 score as a predictor of postoperative outcomes in elderly patients undergoing esophagectomy.

Journal: General thoracic and cardiovascular surgery

Published: June 03, 2026

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.

Journal: International journal of clinical oncology

Published: May 28, 2026

BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer.

BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Semiquantitative CLDN18 expression and clinical outcomes in patients with CLDN18-positive gastric cancer treated with zolbetuximab plus chemotherapy.

Semiquantitative CLDN18 expression and clinical outcomes in patients with CLDN18-positive gastric cancer treated with zolbetuximab plus chemotherapy.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy.

The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Prognostic nutritional index as a prognostic marker in metastatic esophageal squamous-cell carcinoma treated with immune checkpoint inhibitor.

Prognostic nutritional index as a prognostic marker in metastatic esophageal squamous-cell carcinoma treated with immune checkpoint inhibitor.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma.

Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Clinical efficacy of nivolumab-based therapy for HER2-negative diffuse-type advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal dissemination.

Clinical efficacy of nivolumab-based therapy for HER2-negative diffuse-type advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal dissemination.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Treatment outcomes of low-radial-force self-expandable metal stent placement and palliative radiotherapy for unresectable advanced esophageal squamous cell carcinoma with dysphagia.

Treatment outcomes of low-radial-force self-expandable metal stent placement and palliative radiotherapy for unresectable advanced esophageal squamous cell carcinoma with dysphagia.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: November 29, 2025

Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.

Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.

Journal: Targeted oncology

Published: November 17, 2025

Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience.

Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience.

Journal: Journal of cancer research and clinical oncology

Published: November 16, 2025

Showing 1-12 of 161

Last Updated: 09/26/2026